VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.
In addition, VisEn has launched a new near infrared label, VivoTag 800 to add an additional wavelength channel to its current line of VivoTag fluorochromes which are used to label specific ligands of interest in a wide variety of in vivo and in vitro imaging applications. Both of the new 800 nm agents are well suited for imaging quantification on the VisEn FMT 2500(TM) LX quantitative tomography imaging system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and biologies of interest in vivo.
VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 30+ different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense, IntegriSense(TM), AngioSense(TM), OsteoSense, Annexin-Vivo(TM), MMPSense(TM), Cat B FAST(TM), Cat K FAST(TM) and ReninSense(TM) FAST. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag fluorescence labeling dyes for custom agent development, and its NanoSpark labeling nanoparticles, all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new OsteoSense 800 and VivoTag 800 agents, are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.